CA4P

Generic Name: CA4P

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₂O_₆

CAS Number: 222030-63-9

Unique Ingredient Identifier: -

Background: CA4P has been shown in the laboratory to shut down the blood supply to tumours. It is one of the first vascular targeting drugs to be tested in patients. This drug was originally isolated from the African Bush Willow. The first studies in patients with this drug were aimed at finding out whether it can be safely given to patients, what side effects it produces and whether it can actually shut down the blood supply to human tumours.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Oncotelic Therapeutics Implements PDAOAI Platform

Oncotelic Therapeutics launched PDAOAI, an AI platform for document search and analysis, accessible via PDAO tokens. It offers precise queries and contextual answers, benefiting industries like biotechnology. Governed by Pet2DAO, it ensures transparent, community-driven governance. The platform has already aided Sapu Bioscience in achieving GMP compliance.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy